ReviewChemMedChem2026
Exploiting Multicomponent Reactions to Drive the Development of Novel Antitubercular Agents: An Overview.
Review in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Tuberculosis (TB) remains a global epidemic, and Mycobacterium tuberculosis (Mtb), its etiological agent, continues to be the deadliest single infectious agent worldwide. Our inability to eradicate TB is strongly related to Mtb's ability to alternate between an active and latent disease state, and a lack of pharmacological agents that effectively target the heterogeneity of TB, which leads downstream to the emergence of drug resistance. The ongoing quest to discover novel effective chemical agents to improve anti-TB regimens remains a significant challenge. Multicomponent reactions (MCRs) have been shown to generate highly diverse chemical libraries in a time- and cost-efficient, sustainable manner, and thus have emerged as powerful tools to accelerate drug discovery and development. This review provides an overview of the chemical libraries of anti-TB agents developed by MCRs, highlighting the contributions of MCRs to advance anti-TB drug discovery through a medicinal chemistry approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.